Uni Eropa -
Norwegia -
EMA (European Medicines Agency)
ximluci
stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - Øyemidler - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
Norwegia -
Norwegia -
Statens legemiddelverk
velbe 10 mg
stada nordic aps - vinblastinsulfat - pulver til injeksjonsvæske, oppløsning - 10 mg
Norwegia -
Norwegia -
Statens legemiddelverk
moxonidin actavis 0.2 mg
actavis group ptc ehf (1) - moksonidin - tablett, filmdrasjert - 0.2 mg
Norwegia -
Norwegia -
Statens legemiddelverk
moxonidin actavis 0.4 mg
actavis group ptc ehf (1) - moksonidin - tablett, filmdrasjert - 0.4 mg
Norwegia -
Norwegia -
Statens legemiddelverk
modifenac 75 mg
teva b.v. - diklofenaknatrium - kapsel med modifisert frisetting, hard - 75 mg
Norwegia -
Norwegia -
Statens legemiddelverk
pinex 250 mg
actavis group ptc ehf - paracetamol - granulat i dosepose med jordbærsmak - 250 mg
Norwegia -
Norwegia -
Statens legemiddelverk
methylphenidate teva 60 mg
teva b.v. - metylfenidathydroklorid - kapsel med modifisert frisetting, hard - 60 mg
Norwegia -
Norwegia -
Statens legemiddelverk
methylphenidate teva 10 mg
teva b.v. - metylfenidathydroklorid - kapsel med modifisert frisetting, hard - 10 mg
Norwegia -
Norwegia -
Statens legemiddelverk
methylphenidate teva 20 mg
teva b.v. - metylfenidathydroklorid - kapsel med modifisert frisetting, hard - 20 mg
Norwegia -
Norwegia -
Statens legemiddelverk
methylphenidate teva 30 mg
teva b.v. - metylfenidathydroklorid - kapsel med modifisert frisetting, hard - 30 mg